Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA

AIDS

Volumn 14, Issue 4, 2000, Pages 415-421

  Cu Uvin, Susan ^a,d   Caliendo, Angela M ^b   Reinert, Steven ^c   Chang, Albert ^a   Juliano Remollino, Catherine ^a   Flanigan, Timothy P ^a   Mayer, Kenneth H ^a   Carpenter, Charles C J ^a  

^a BROWN UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Lifespan   (United States)

^d MIRIAM HOSPITAL   (United States)

Author keywords

Antiretroviral therapy; Cervicovaginal; HIV 1 RNA

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; EFAVIRENZ; INDINAVIR; NELFINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENITAL SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LAVAGE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CANDIDIASIS, VULVOVAGINAL; CERVIX UTERI; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; VAGINA;

EID: 0034026101     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200003100-00015     Document Type: Article

References (26)

1. 1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Mod 1997, 337:725-733.
2. 2. Carpenter CCJ, Fischl MA, Hammer S, et al. Antiretroviral therapy for HIV infection in 1997: recommendations of an international panel. JAMA 1997, 277:1962-1969.
3. 3. Vernazza PL, Gilliam BL, Flepp M, et al. Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS 1997, 11:1249-1254.
4. 4. Gupta P, Mellors J, Kingsley L, et al. High viral load in semen of human immunodeficiency virus type 1 infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors. J Virol 1997, 71:1-5.
5. 5. Gilliam BL, Dyer JR, Fiscus SA, et al. Effects of reverse transcriptase inhibitor therapy on the HIV-1 burden in semen. J Acquired Immune Defic Syndr Hum Retrovirol 1997, 15:54-60.
6. 6. Kreiss JK, Coombs R, Plummer F, et al. Isolation of human immunodeficiency virus from genital ulcers in Nairobi prostitutes. J Infect Dis 1989, 160:380-384.
7. 7. Henin Y, Mandelbrot L, Henrion R, Pradinaud R, Coulaud JP, Montagnier L. Virus excretion on cervicovaginal secretions of pregnant and non-pregnant HIV-infected women. J Acquired Immune Defic Syndr 1993, 6:72-75.
8. 8. Goulston C, McFarland W, Katzenstein D. Human immunodeficiency viruses type 1 RNA in the female genital tract. J Infect Dis 1998, 177:110-113.
9. 9. Kreiss J, Willerford DM, Hensel M, et al. Association between cervical inflammation and cervical shedding of human immunodeficiency virus DNA. J Infect Dis 1994, 170:1597-1601.
10. 10. John GC, Nduati RW, Mbori-Ngacha D, et al. Genital shedding of human immunodeficiency virus type 1 DNA during pregnancy: association with immunosuppression, abnormal cervical or vaginal discharge, and severe vitamin A deficiency. J Infect Dis 1997, 175:57-62.
11. 11. Iversen AKN, Larsen AR, Jensen T, et al. Distinct determinants of human immunodeficiency virus type 1 RNA and DNA loads in vaginal and cervical secretions. J Infect Dis 1998, 177:1214-1220.
12. 12. Shaheen F, Sison AV, McIntosh L, Mukhtar M, Pomerantz RJ. Analysis of HIV-1 in the cervicovaginal secretions and blood of pregnant and nonpregnant women. J Hum Virol 1999, 2:154-166.
13. 13. Loussert-Ajaka I, Mandelbrot L, Delmas MC, et al. HIV-1 detection in cervicovaginal secretions during pregnancy. AIDS 1997, 22:1575-1581.
14. 14. Cu-Uvin S, Caliendo AM. Cervicovaginal human immunodeficiency virus secretion and plasma viral load in human immunodeficiency virus-seropositive women. Obstet Gynecol 1997, 90:739-743.
15. 15. Hart CE, Lennox JL, Pratt-Palmore M, et al. Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract. J Infect Dis 1999, 179:871-882.
16. 16. Rasheed S, Zhiliang L, Dong X, Kovac A. Presence of cell-free human immunodeficiency virus in cervicovaginal secretions is independent of viral load in the blood of human immunodeficiency virus-infected women. Am J Obstet Gynecol 1996, 175:122-130.
17. 17. Zhu T, Wang N, Carr A, et al. Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J Virol 1996, 70:3098-3107.
18. 18. Coombs RW, Speck CE, Hughes JP, et al. Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1RNA levels in semen and blood: evidence for compartmentalization of HIV-1 between semen and blood. J Infect Dis 1998, 177:320-330.
19. 19. Eron JJ, Vernazza PL, Johnston DM, et al. Resistance to HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission. AIDS 1998, 12:F181-F189.
20. 20. Garcia PM, Kalishi LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Engl J Med 1999, 341:394-402.
21. 21. Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. N Engl J Med 1999, 341:385-393.
22. 22. Cao Y, Krogstad P, Korber BT, et al. Maternal HIV-1 viral load and vertical transmission of infection: the Ariel Project for the prevention of HIV transmission from mother to infant. Nat Med 1997, 3:549-552.
23. 23. Sperling RS, Shapiro DE, Cooms RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996, 335:1621-1629.
24. 24. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
25. 25. Zhang H, Dornadulla G, Beumont M, et al. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med 1998, 339: 1803-1809.
26. 26. Mayer KH, Boswell S, Goldstein R, et al. Persistence of human immunodeficiency virus in semen after adding indinavir to combination antiretroviral therapy. Clin Infect Dis 1999, 28:1252-1259.